GLP1R agonist/PCSK9 inhibitor (Novo Nordisk)

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameGLP1R agonist/PCSK9 inhibitor (Novo Nordisk)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsProprotein convertase subtilisin kexin type 9 inhibitors
TargetsGlucagon-like peptide 1 receptorProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A